---
title: "Cytopathology"
order: 6
category: "Clinical Pathology"
---

# Cytopathology

## Overview

Cytopathology is the diagnostic subspecialty that examines individual cells and small clusters of cells from body fluids, aspirates, and exfoliative specimens to diagnose disease. Unlike histopathology which evaluates tissue architecture, cytopathology focuses on cellular morphology, nuclear features, and cytoplasmic characteristics. Cytopathology plays a critical role in cancer screening (cervical Pap smears), diagnosis (fine needle aspiration), and rapid intraoperative consultation. It offers advantages of minimal invasiveness, rapid results, and cost-effectiveness compared to surgical biopsy.

### Scope of Practice
- Gynecologic cytology (Pap smears, cervical cancer screening)
- Non-gynecologic exfoliative cytology (urine, sputum, body fluids)
- Fine needle aspiration (FNA) cytology
- Rapid on-site evaluation (ROSE)
- Liquid-based cytology
- Ancillary techniques (immunocytochemistry, molecular testing)

### Clinical Significance
- Early cancer detection and prevention
- Minimally invasive diagnosis
- Rapid intraoperative diagnosis
- Triage for additional testing
- Cost-effective screening and diagnosis
- Reduced patient morbidity

## Fundamental Principles

### Cytologic vs. Histologic Diagnosis

#### Cytopathology Advantages
- **Minimally invasive**: Needle aspiration vs. surgical biopsy
- **Rapid results**: Immediate to 24-48 hours
- **Cost-effective**: Lower procedural costs
- **Safer**: Reduced complications
- **Multiple sampling**: Can repeat easily
- **Preserved architecture**: Tissue available for other studies

#### Cytopathology Limitations
- **No tissue architecture**: Cannot assess invasion
- **Sampling error**: May miss lesion
- **Small samples**: Limited material for ancillary studies
- **Interpretation challenges**: Experience-dependent
- **Higher inadequate rate**: Compared to tissue biopsy

### Specimen Types

#### Exfoliative Cytology
- **Definition**: Spontaneously shed or abraded cells
- **Sources**: Cervix, urine, sputum, effusions, brushings
- **Advantages**: Non-invasive or minimally invasive
- **Applications**: Screening, diagnosis

#### Aspiration Cytology
- **Definition**: Cells aspirated with needle
- **Technique**: Fine needle aspiration (FNA)
- **Advantages**: Direct sampling of lesion
- **Applications**: Palpable masses, image-guided biopsies

### Cytologic Features of Malignancy

#### Nuclear Abnormalities
- **Enlargement**: Increased nuclear size
- **Pleomorphism**: Variation in size and shape
- **Hyperchromasia**: Increased chromatin density
- **Irregular membranes**: Notching, grooves, irregularity
- **Prominent nucleoli**: Large, irregular, multiple
- **Abnormal chromatin**: Coarse, clumped, irregular distribution
- **Increased N:C ratio**: Nuclear enlargement relative to cytoplasm

#### Cytoplasmic Changes
- **Decreased volume**: High N:C ratio
- **Staining changes**: Basophilia, vacuolation
- **Inclusions**: Abnormal substances

#### Architectural Features
- **Loss of cohesion**: Single cells, loosely cohesive clusters
- **Disordered arrangement**: Loss of polarity
- **Crowding and overlap**: Three-dimensional clusters
- **Molding**: Nuclear compression

## Gynecologic Cytology

### Cervical Cancer Screening

#### Papanicolaou (Pap) Test History
- **George Papanicolaou**: Developed technique in 1940s
- **Impact**: Reduced cervical cancer mortality by >70%
- **Evolution**: Conventional smears to liquid-based cytology
- **Integration**: HPV testing for improved screening

#### Specimen Collection

##### Conventional Pap Smear
- **Technique**: Direct smear on glass slide
- **Fixation**: Immediate alcohol fixation
- **Advantages**: Low cost, established
- **Disadvantages**: Obscuring blood/inflammation, sampling variability

##### Liquid-Based Cytology
- **Technique**: Cells suspended in fixative solution
- **Processing**: Automated thin-layer preparation
- **Advantages**: Reduced obscuring elements, HPV testing, improved adequacy
- **Platforms**: ThinPrep, SurePath
- **Adoption**: Standard in many countries

#### Specimen Adequacy

##### Satisfactory for Evaluation
- **Cellularity**: Minimum 5,000 squamous cells (conventional) or estimated (LBC)
- **Transformation zone**: Endocervical/metaplastic cells present
- **Well-preserved**: Proper fixation
- **Well-visualized**: <75% obscured

##### Unsatisfactory for Evaluation
- **Insufficient cells**: <5,000 squamous cells
- **Poor preservation**: Air-drying artifact
- **Obscured**: >75% by blood, inflammation, lubricant
- **Unlabeled**: Identification issues

### The Bethesda System (TBS)

#### Negative for Intraepithelial Lesion or Malignancy (NILM)
- **Normal cellular components**: Squamous, glandular, metaplastic
- **Reactive changes**: Inflammation, repair, radiation, IUD
- **Organisms**: Trichomonas, Candida, Actinomyces, bacterial vaginosis, herpes

#### Epithelial Cell Abnormalities

##### Squamous Cells

###### Atypical Squamous Cells (ASC)
- **ASC-US**: Of undetermined significance (5-10% of Paps)
  - **Management**: HPV testing (reflex or co-test)
  - **If HPV positive**: Colposcopy
  - **If HPV negative**: Routine screening
- **ASC-H**: Cannot exclude HSIL
  - **Management**: Colposcopy
  - **Risk**: 24-94% have CIN2+ on biopsy

###### Low-Grade Squamous Intraepithelial Lesion (LSIL)
- **Histologic correlate**: CIN 1, HPV effect
- **Features**:
  - Nuclear enlargement (3× intermediate cell nucleus)
  - Hyperchromasia
  - Irregular nuclear membranes
  - Koilocytosis (perinuclear halo)
- **Management**: HPV testing, colposcopy (age-dependent)
- **Regression rate**: 60% spontaneous regression

###### High-Grade Squamous Intraepithelial Lesion (HSIL)
- **Histologic correlate**: CIN 2, CIN 3, carcinoma in situ
- **Features**:
  - Smaller cells
  - Marked nuclear enlargement (N:C ratio >1:2)
  - Severe hyperchromasia
  - Irregular nuclear membranes
  - Abnormal chromatin
- **Management**: Immediate colposcopy
- **Cancer risk**: 2% invasive cancer, 70% CIN2+

###### Squamous Cell Carcinoma
- **Features**:
  - Severe nuclear abnormalities
  - Tumor diathesis (necrotic debris)
  - Single cells and irregular clusters
- **Types**: Keratinizing, non-keratinizing
- **Management**: Colposcopy, biopsy, staging

##### Glandular Cells

###### Atypical Glandular Cells (AGC)
- **Subtypes**: Endocervical, endometrial, NOS
- **Risk**: 9-38% significant pathology (CIN2+, adenocarcinoma)
- **Management**: Colposcopy with endocervical sampling, ±endometrial biopsy

###### Adenocarcinoma
- **Types**: Endocervical, endometrial, extrauterine
- **Features**: Columnar cells, nuclear crowding, prominent nucleoli
- **Management**: Colposcopy, biopsy, staging

### Screening Guidelines

#### American Cancer Society (ACS) 2020 Guidelines
- **Age 21-29**: Cytology alone every 3 years
- **Age 30-65**: HPV testing alone every 5 years (preferred) OR co-testing every 5 years OR cytology alone every 3 years
- **Age >65**: Discontinue if adequate prior screening, no CIN2+ in 25 years
- **Post-hysterectomy**: Discontinue if no cervix, no history of CIN2+ or cancer

#### High-Risk Populations
- **HIV positive**: Annual screening
- **Immunosuppressed**: Annual or more frequent
- **DES exposure**: Annual
- **History CIN2+**: Continued surveillance per guidelines

### Human Papillomavirus (HPV)

#### Virology
- **Family**: Papillomaviridae, DNA virus
- **Types**: >200 identified, ~40 infect genital tract
- **High-risk types**: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68
- **Low-risk types**: 6, 11 (genital warts)

#### Oncogenesis
- **E6 protein**: Inactivates p53
- **E7 protein**: Inactivates Rb
- **Integration**: Viral DNA into host genome
- **Progression**: HPV infection → CIN 1 → CIN 2/3 → invasive cancer
- **Timeline**: 10-20 years average progression

#### HPV Testing
- **Detection**: High-risk HPV DNA or RNA
- **Methods**: Hybrid Capture 2, PCR-based assays
- **Uses**: Primary screening, ASC-US triage, post-treatment surveillance
- **Genotyping**: HPV 16/18 identification for risk stratification

## Non-Gynecologic Cytology

### Respiratory Cytology

#### Sputum Cytology
- **Indications**: Lung cancer screening (limited role), diagnosis
- **Collection**: Deep cough, early morning, 3-5 samples
- **Adequacy**: Alveolar macrophages present
- **Limitations**: Low sensitivity (60-80%), operator dependent
- **Findings**: Malignant cells, infectious organisms, inflammatory cells

#### Bronchial Brushings and Washings
- **Collection**: During bronchoscopy
- **Advantages**: Higher yield than sputum
- **Sensitivity**: 75-90% for central lesions, lower for peripheral
- **Adequacy**: Respiratory epithelial cells, alveolar macrophages

#### Bronchoalveolar Lavage (BAL)
- **Indications**: Diffuse lung disease, infection, malignancy
- **Collection**: Saline instillation and aspiration
- **Cell differential**: Lymphocytes, neutrophils, eosinophils, macrophages
- **Infectious workup**: Stains, cultures, molecular tests
- **Malignancy**: Lymphoma, adenocarcinoma

### Urinary Cytology

#### Indications
- **Hematuria evaluation**: Exclude urothelial carcinoma
- **Surveillance**: History of urothelial carcinoma
- **Screening**: Occupational exposure (limited role)

#### Specimen Collection
- **Voided urine**: Midstream, fresh specimen
- **Catheterized specimen**: Higher cellularity
- **Bladder washing**: During cystoscopy
- **Timing**: Second morning void preferred (first morning degenerative changes)

#### Paris System for Reporting Urinary Cytology

##### Unsatisfactory
- **Scant cellularity**: <20 umbrella/superficial cells (voided)
- **Obscuring factors**: Excess blood, inflammation, lubricant

##### Negative for High-Grade Urothelial Carcinoma
- **Benign urothelial cells**: Normal morphology
- **Reactive changes**: Inflammation, lithiasis, instrumentation
- **Polyomavirus**: Decoy cells

##### Atypical Urothelial Cells
- **Features**: Nuclear atypia exceeding reactive but insufficient for malignancy
- **N:C ratio**: Mildly increased
- **Chromatin**: Mildly hyperchromatic
- **Management**: Repeat cytology, cystoscopy

##### Suspicious for High-Grade Urothelial Carcinoma
- **Features**: Worrisome but qualitatively or quantitatively insufficient
- **Severe atypia**: Few atypical cells
- **Degeneration**: Obscures definitive diagnosis

##### High-Grade Urothelial Carcinoma
- **Features**:
  - Markedly increased N:C ratio (>0.7)
  - Hyperchromasia
  - Irregular nuclear membranes
  - Coarse chromatin
- **Patterns**: Single cells, three-dimensional clusters
- **Sensitivity**: 80-90% for high-grade
- **Specificity**: >95%

##### Low-Grade Urothelial Neoplasia
- **Rarely diagnosed**: Poor cytologic-histologic correlation
- **Features**: Minimal atypia, papillary fragments
- **Sensitivity**: Low (10-40%)

### Body Fluid Cytology

#### Pleural Fluid

##### Indications
- **Effusion evaluation**: Transudative vs. exudative
- **Malignancy detection**: Lung, breast, ovary, lymphoma
- **Infection**: Empyema

##### Specimen Processing
- **Volume**: 50-100 mL preferred
- **Fresh specimen**: Immediate processing
- **Anticoagulant**: EDTA or heparin
- **Cell block**: Concentrate, formalin-fixed for IHC

##### Cytologic Findings
- **Benign mesothelial cells**: Reactive lining cells
- **Inflammatory cells**: Neutrophils, lymphocytes, eosinophils
- **Malignant cells**:
  - **Adenocarcinoma**: Most common, three-dimensional clusters
  - **Mesothelioma**: Mesothelial proliferation, immunostains distinguish
  - **Lymphoma**: Monotonous lymphoid population, flow cytometry

##### Diagnostic Categories
- **Negative**: No malignant cells
- **Atypical**: Reactive vs. neoplastic uncertain
- **Suspicious**: Highly suggestive, not definitive
- **Positive**: Malignant cells identified
- **Sensitivity**: 60-70% overall, higher for subsequent taps

#### Peritoneal Fluid (Ascites)

##### Causes
- **Transudative**: Cirrhosis, heart failure, hypoalbuminemia
- **Exudative**: Infection, malignancy, pancreatitis
- **Serum-ascites albumin gradient (SAAG)**: >1.1 g/dL suggests portal hypertension

##### Malignancy
- **Primary**: Ovarian, gastric, pancreatic carcinoma
- **Secondary**: Breast, lung, lymphoma
- **Peritoneal carcinomatosis**: Widespread metastases
- **Sensitivity**: 50-70% on first tap, 80-90% after multiple taps

#### Pericardial Fluid

##### Indications
- **Pericardial effusion**: Malignancy, infection, inflammation
- **Less common**: Than pleural or peritoneal fluids

##### Malignancy
- **Lung carcinoma**: Most common primary
- **Breast carcinoma**: Second most common
- **Lymphoma**: Especially in HIV
- **Mesothelioma**: Rare, pericardial primary

#### Cerebrospinal Fluid (CSF)

##### Indications
- **Meningitis**: Bacterial, viral, fungal, tuberculous
- **Malignancy**: Leptomeningeal carcinomatosis, CNS lymphoma, leukemia

##### Specimen Handling
- **Fresh specimen**: Process immediately (cells degenerate rapidly)
- **Volume**: 10-15 mL for cytology
- **Cytocentrifugation**: Concentrate cells
- **Cell count and differential**: Concurrent studies

##### Cytologic Findings
- **Normal**: Rare lymphocytes and monocytes (<5 cells/μL)
- **Increased lymphocytes**: Viral, tuberculous, fungal, lymphoma
- **Increased neutrophils**: Bacterial meningitis
- **Malignant cells**:
  - **Carcinoma**: Lung, breast, melanoma
  - **Lymphoma/leukemia**: Primary CNS lymphoma, ALL
  - **Glioblastoma**: Rare in CSF
- **Sensitivity**: 80-90% with repeated taps

## Fine Needle Aspiration (FNA) Cytology

### Technique

#### Aspiration Technique
- **Needle size**: 22-27 gauge (thinner for vascular organs)
- **Syringe**: 10-20 mL
- **Passes**: Multiple (4-6) from different angles
- **Suction**: Apply negative pressure during sampling
- **Release**: Before withdrawal to prevent aspiration into syringe
- **Capillary technique**: No suction for vascular lesions

#### Image Guidance
- **Palpation-guided**: Superficial, palpable masses
- **Ultrasound-guided**: Real-time visualization, safe for deep lesions
- **CT-guided**: Deep, non-palpable lesions
- **Endoscopic ultrasound (EUS)**: Pancreas, mediastinal, GI wall lesions

#### Rapid On-Site Evaluation (ROSE)
- **Purpose**: Assess adequacy, triage specimen
- **Procedure**: Immediate evaluation of smears
- **Benefits**: Reduced inadequate rate, optimal specimen handling
- **Cytopathologist/cytotechnologist**: Present during procedure
- **Communication**: Immediate feedback to proceduralist

### Specimen Preparation

#### Direct Smears
- **Air-dried**: Romanowsky stains (Diff-Quik, Giemsa)
- **Alcohol-fixed**: Papanicolaou stain
- **Advantages**: Rapid, preserves cytoplasmic detail
- **Both preparations**: Complementary information

#### Liquid-Based Cytology
- **Rinse in fixative**: Preservative solution
- **Automated processing**: Standardized preparation
- **Advantages**: Ancillary testing, reduced obscuring elements

#### Cell Block
- **Preparation**: Pellet from rinse/aspirate, formalin-fixed, paraffin-embedded
- **Advantages**: Tissue architecture, immunohistochemistry, molecular testing
- **Essential**: Limited diagnostic material

### Adequacy Criteria

#### General Principles
- **Cellularity**: Sufficient diagnostic cells
- **Preservation**: Well-fixed, interpretable
- **Representation**: Sampling of target lesion
- **Site-specific criteria**: Vary by organ

#### Common Sites

##### Thyroid
- **Adequate**: 6 groups of 10-15 follicular cells (cyst excluded)
- **Inadequate**: <6 groups or predominantly cyst contents
- **Re-aspiration**: Recommended for inadequate samples

##### Lymph Node
- **Adequate**: Diagnostic cells or lymphoid population for flow cytometry
- **Variable**: Depends on clinical question

### Diagnostic Categories and Applications

#### Thyroid FNA - Bethesda System

##### I. Non-Diagnostic/Unsatisfactory
- **Frequency**: 10-15%
- **Management**: Repeat FNA

##### II. Benign
- **Frequency**: 60-70%
- **Examples**: Nodular goiter, thyroiditis, lymphocytic thyroiditis
- **Malignancy risk**: <3%
- **Management**: Clinical follow-up

##### III. Atypia of Undetermined Significance (AUS)/Follicular Lesion of Undetermined Significance (FLUS)
- **Frequency**: 5-10%
- **Malignancy risk**: 10-30%
- **Management**: Repeat FNA, molecular testing, lobectomy

##### IV. Follicular Neoplasm/Suspicious for Follicular Neoplasm
- **Frequency**: 10-25%
- **Includes**: Follicular adenoma vs. carcinoma, Hürthle cell neoplasm
- **Malignancy risk**: 25-40%
- **Management**: Lobectomy, molecular testing
- **Note**: Cannot distinguish adenoma from carcinoma cytologically (requires capsular/vascular invasion)

##### V. Suspicious for Malignancy
- **Frequency**: 3-5%
- **Malignancy risk**: 60-75%
- **Management**: Lobectomy or total thyroidectomy

##### VI. Malignant
- **Frequency**: 5-10%
- **Types**: Papillary carcinoma (most common), medullary, anaplastic, lymphoma, metastatic
- **Malignancy risk**: 95-100%
- **Management**: Total thyroidectomy (usually)

##### Papillary Thyroid Carcinoma Features
- **Nuclear features**: Enlarged, overlapping nuclei
- **Nuclear grooves**: Longitudinal grooves
- **Nuclear pseudoinclusions**: Intranuclear cytoplasmic invaginations
- **Chromatin**: "Ground glass" or powdery
- **Papillae**: Fibrovascular cores

#### Salivary Gland FNA - Milan System

##### Categories
- **I**: Non-diagnostic
- **II**: Non-neoplastic
- **III**: Atypia of undetermined significance
- **IV**: Neoplasm
  - **IVA**: Benign neoplasm (pleomorphic adenoma, Warthin tumor)
  - **IVB**: Salivary gland neoplasm of uncertain malignant potential
- **V**: Suspicious for malignancy
- **VI**: Malignant

##### Common Lesions
- **Pleomorphic adenoma**: Most common benign salivary tumor
- **Warthin tumor**: Oncocytic cells, lymphocytes
- **Mucoepidermoid carcinoma**: Mucous, intermediate, epidermoid cells
- **Adenoid cystic carcinoma**: Cylinders, hyaline material

#### Lymph Node FNA

##### Reactive Hyperplasia
- **Polymorphous lymphoid population**: Small, large lymphocytes, plasma cells
- **Tingible body macrophages**: Phagocytosed debris
- **Polyclonal**: Flow cytometry

##### Lymphoma
- **Monomorphous population**: Predominant cell type
- **Monoclonal**: Flow cytometry (B or T cell)
- **Diagnosis**: Requires immunophenotyping
- **Cell block**: Essential for architecture, immunohistochemistry
- **Excisional biopsy**: Often needed for definitive classification

##### Metastatic Carcinoma
- **Cohesive epithelial clusters**: Glandular or squamous
- **Background**: Lymphocytes, debris
- **Immunocytochemistry**: Identify primary site (CK7, CK20, TTF-1, etc.)
- **Clinical correlation**: Essential

##### Granulomatous Inflammation
- **Epithelioid histiocytes**: Cohesive aggregates
- **Multinucleated giant cells**: Langhans or foreign body type
- **Necrosis**: Present in tuberculosis
- **Stains and cultures**: AFB, fungal

#### Breast FNA

##### Declining Use
- **Core needle biopsy**: Preferred (provides architecture for invasion assessment)
- **Limited role**: Palpable masses in resource-limited settings

##### Categories
- **C1**: Inadequate
- **C2**: Benign
- **C3**: Atypia
- **C4**: Suspicious
- **C5**: Malignant

##### Fibroadenoma
- **Cohesive clusters**: "Staghorn" pattern
- **Biphasic**: Epithelial and stromal components
- **Bare nuclei**: Myoepithelial

##### Carcinoma
- **Ductal**: Cellular, pleomorphic, discohesive
- **Lobular**: Single cells, targetoid pattern
- **Immunocytochemistry**: ER, PR, HER2

#### Lung FNA

##### Benign Findings
- **Normal respiratory epithelium**: Ciliated columnar cells
- **Alveolar macrophages**: Hemosiderin, anthracotic pigment
- **Inflammatory**: Lymphocytes, neutrophils

##### Adenocarcinoma
- **Most common**: Primary lung cancer
- **Features**: Glandular clusters, nuclear atypia, prominent nucleoli
- **Immunostains**: TTF-1+, Napsin A+ (primary lung)
- **Molecular testing**: EGFR, ALK, ROS1, PD-L1

##### Squamous Cell Carcinoma
- **Keratinization**: Dense cytoplasm
- **Nuclear features**: Hyperchromasia, irregular membranes
- **Immunostains**: p40+, p63+

##### Small Cell Carcinoma
- **Small cells**: Scant cytoplasm
- **Nuclear molding**: Compression artifact
- **Chromatin**: "Salt and pepper"
- **Immunostains**: Chromogranin, synaptophysin, CD56
- **Poor prognosis**: Aggressive

#### Pancreas FNA (EUS-Guided)

##### Ductal Adenocarcinoma
- **Desmoplastic stroma**: Diagnostic challenge
- **Atypical epithelial cells**: Clusters, single cells
- **Mucin production**: Variable
- **Immunostains**: CK7+, CK20+/-, CDX2+/-
- **Molecular**: KRAS mutations (>90%)

##### Pancreatic Neuroendocrine Tumor
- **Monotonous cells**: Plasmacytoid, "salt and pepper" chromatin
- **Immunostains**: Chromogranin+, synaptophysin+
- **Ki-67 index**: Grading

##### Cystic Lesions
- **Pseudocyst**: Inflammatory debris, no epithelium
- **Serous cystadenoma**: Glycogen-rich cuboidal cells
- **Mucinous cystic neoplasm**: Mucin, atypical epithelium
- **IPMN**: Papillary fragments, mucin, variable atypia
- **Cyst fluid analysis**: CEA, amylase, molecular (KRAS, GNAS)

## Ancillary Techniques

### Immunocytochemistry

#### Principles
- **Antibody binding**: Specific protein detection
- **Visualization**: Chromogen or fluorescence
- **Cell block sections**: Optimal for immunostaining
- **Smears**: Possible but less reliable

#### Applications
- **Tumor classification**: Epithelial vs. mesenchymal vs. lymphoid
- **Primary site**: CK7/CK20 pattern, organ-specific markers
- **Prognostic markers**: ER, PR, HER2 in breast
- **Predictive markers**: PD-L1 for immunotherapy

#### Common Panels
- **Carcinoma**: Pancytokeratin (AE1/AE3, CAM5.2)
- **Adenocarcinoma primary site**:
  - Lung: TTF-1, Napsin A
  - GI: CDX2, CK20
  - Pancreaticobiliary: CK7, CK19
  - Breast: GATA3, mammaglobin
  - Prostate: PSA, NKX3.1
  - Thyroid: TTF-1, thyroglobulin

### Molecular Testing

#### DNA-Based Tests
- **Mutation analysis**: EGFR, KRAS, BRAF
- **Gene rearrangements**: ALK, ROS1, RET
- **Microsatellite instability**: Lynch syndrome
- **HPV genotyping**: Cervical specimens

#### RNA-Based Tests
- **Gene expression**: mRNA levels
- **Fusion transcripts**: EML4-ALK, ETV6-NTRK3
- **microRNA**: Diagnostic and prognostic

#### Applications in Cytology
- **Cell block**: DNA/RNA extraction
- **Liquid-based cytology**: Residual specimen
- **Thyroid**: BRAF, RAS, RET/PTC
- **Lung**: EGFR, ALK, ROS1, PD-L1
- **Limitations**: Small sample size, tumor percentage

### Flow Cytometry

#### Principles
- **Cell suspension**: Fresh specimen required
- **Antibody labeling**: Fluorescent detection
- **Multi-parameter**: Simultaneous marker assessment
- **Quantitative**: Cell percentages

#### Applications
- **Lymphoma diagnosis**: B vs. T cell, clonality
- **Leukemia**: Immunophenotyping, MRD
- **Body fluids**: Lymphoma, leukemia detection
- **Fresh specimen**: Essential (within 24 hours)

## Quality Assurance

### Screening and Interpretation

#### Two-Tier System
- **Cytotechnologist screening**: Initial review
- **Pathologist interpretation**: Abnormal cases, random rescreening
- **Workload limits**: Maximum cases per day (CAP guidelines)

#### Quality Control
- **10% random rescreening**: Negative cases
- **100% high-risk rescreening**: Prior abnormal, high-risk patients
- **Rapid review**: All cases (brief examination)
- **Correlation with histology**: Cytology-histology concordance

### Performance Metrics

#### Adequacy Rate
- **Target**: >90% satisfactory
- **Monitoring**: By screener, site, specimen type

#### False Negative Rate
- **Pap test**: <5% (CAP guideline)
- **Calculation**: FN / (FN + TP) on histologic follow-up
- **Review**: All false negatives

#### Positive Predictive Value
- **Cytology-histology correlation**: Agreement percentage
- **Target**: >80% for malignant diagnoses

### Proficiency Testing

#### External Quality Assessment
- **CAP proficiency surveys**: Semi-annual
- **Competency**: Maintain certification
- **Benchmarking**: Compare with peers

## Limitations and Pitfalls

### Sampling Issues
- **Inadequate cellularity**: Non-representative
- **Sampling error**: Missed lesion
- **Heterogeneous lesions**: Partial sampling

### Interpretive Challenges
- **Mimickers**: Reactive vs. malignant
- **Limited material**: Ancillary testing constraints
- **Obscuring factors**: Blood, inflammation, necrosis
- **Degeneration**: Poor preservation

### Specific Pitfalls
- **Reactive mesothelial cells**: Mimic adenocarcinoma
- **Viral cytopathic effect**: Mimic dysplasia (HPV, herpes)
- **Reparative changes**: Mimic malignancy
- **Degeneration**: False negative interpretation

## Key Points

- Cytopathology provides minimally invasive diagnosis with rapid results
- Pap smear screening has dramatically reduced cervical cancer mortality
- The Bethesda System standardizes gynecologic cytology reporting
- HPV testing enhances cervical cancer screening and triage
- Fine needle aspiration offers diagnostic accuracy comparable to biopsy for many sites
- Thyroid FNA uses Bethesda System with six diagnostic categories
- Rapid on-site evaluation (ROSE) improves FNA adequacy rates
- Body fluid cytology evaluates effusions for malignancy and infection
- Ancillary techniques (immunocytochemistry, molecular, flow cytometry) enhance diagnostic accuracy
- Quality assurance programs ensure high diagnostic standards and minimize errors

## References

1. Bibbo M, Wilbur DC. Comprehensive Cytopathology. 4th ed. Elsevier; 2015.
2. Nayar R, Wilbur DC. The Bethesda System for Reporting Cervical Cytology. 3rd ed. Springer; 2015.
3. Cibas ES, Ali SZ. The 2017 Bethesda System for Reporting Thyroid Cytopathology. Thyroid. 2017;27(11):1341-1346.
4. Rosenthal DL, Wojcik EM, Kurtycz DFI. The Paris System for Reporting Urinary Cytology. Springer; 2016.
5. Rossi ED, Faquin WC, Baloch Z, et al. The Milan System for Reporting Salivary Gland Cytopathology. Springer; 2018.
6. Krane JF, Faquin WC, Renshaw AA. Essential of Cytopathology. Cambridge University Press; 2013.
7. Orell SR, Sterrett GF. Orell and Sterrett's Fine Needle Aspiration Cytology. 6th ed. Elsevier; 2020.
8. American Cancer Society. Cervical Cancer Screening Guidelines. CA Cancer J Clin. 2020;70(5):321-346.
9. College of American Pathologists. Gynecologic Cytology Quality Assurance Guidelines. 2023.
10. Pitman MB, Layfield LJ. Guidelines for pancreaticobiliary cytology from the Papanicolaou Society of Cytopathology. Diagn Cytopathol. 2014;42(4):340-346.
